The company found this on their own without FDA interaction and I would guess after all the recalls, they are probably going through everything with a fine tooth comb. This is not a recall that affects a real large group of consumers but still it’s one more product found not to be up to standards. Back in January Wall Street was asking Bill Weldon, the CEO as to when the recalls might either stop or at least slow down. BD
Wall Street Asks J and J CEO About Recalls and As A Bonus Question, When He Plans to Step Down on Conference Call
Besides their own problems they have some counterfeiters to look out for as well.
Counterfeit Johnson & Johnson OneTouch Products Investigation – One More Good Reason to Start “Tagging” Products for Consumers So We Can Scan for Authenticity
Again, Johnson and Johnson with all their products in so many different areas of healthcare could sure stand to build consumer, doctor and business confidence about now and it sure beats being the BP of the pharmaceutical and medical devices industry and my bar coding idea still stands. BD
Johnson & Johnson has recalled about 70,000 syringes of an injectable formulation of the antipsychotic Invega after discovering cracks in the syringes, which could potentially lead to infections or reduced efficacy in users.
J&J, which has issued a series of recalls of various products due to manufacturing-quality problems since 2009, sent notice of the recall of Invega Sustenna to distributors, pharmacists and health-care providers on Feb. 11, according to a company website. The recall affects products sold in the U.S., Australia, Canada and South Korea.
The recalled syringes contain 234-milligram dosages of Invega Sustenna, which were distributed beginning in March 2010. Other dosage strengths of the drug aren't being recalled.
J&J said some of the prefilled syringes containing Invega Sustenna had a crack in the syringe barrel, which isn't detectable by the user because the cracks are covered by labels. The cracks may have been caused by stress during the label application process, said J&J spokesman Greg Panico. J&J discovered the flaw in routine testing, he said.